Key result
Simvastatin therapy significantly attenuated G-CSF-induced cardiac thrombosis in an iron-loading mouse model, reducing thrombus incidence from 70% to 20%.
Why the study?
Does simvastatin prevent G-CSF-induced cardiac thrombosis in an iron-loaded mouse model?
Does simvastatin prevent G-CSF-induced cardiac thrombosis in an iron-loaded mouse model?
Simvastatin, but not tirofiban, attenuates G-CSF-induced cardiac thrombosis in an iron-loaded mouse model by reducing systemic inflammation and leukocytosis.
Does not support clinical use; leaves open translation of simvastatin effects from this iron-loaded mouse model.
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF), a hematopoietic cytokine, was recently used to treat patients of acute myocardial infarction with beneficial effect. However, controversy exists as some patients developed re-stenosis and worsened condition post G-CSF delivery. This study presents a new disease model to study G-CSF induced cardiac thrombosis and delineate its possible mechanism. We used iron loading to mimic condition of chronic cardiac dysfunction and apply G-CSF to mice to test our hypothesis. METHODS AND RESULTS: Eleven out of fifteen iron and G-CSF treated mice (I+G) showed thrombi formation in the left ventricular chamber with impaired cardiac function. Histological analysis revealed endothelial fibrosis, increased macrophage infiltration and tissue factor expression in the I+G mice hearts. Simvastatin treatment to I+G mice attenuated their cardiac apoptosis, iron deposition, and abrogated thrombus formation by attenuating systemic inflammation and leukocytosis, which was likely due to the activation of pAKT activation. However, thrombosis in I+G mice could not be suppressed by platelet receptor inhibitor, tirofiban. CONCLUSIONS: Our disease model demonstrated that G-CSF induces cardiac thrombosis through an inflammation-thrombosis interaction and this can be attenuated via statin therapy. Present study provides a mechanism and potential therapy for G-CSF induced cardiac thrombosis.
No takes yet. Share an insight, caveat, or question.
Lian et al. (2011) studied Cardiac thrombosis. Simvastatin vs. No simvastatin (I+G group) was evaluated on Incidence of intra-cardiac thrombus formation (p=<0.05). Simvastatin therapy significantly attenuated G-CSF-induced cardiac thrombosis in an iron-loading mouse model, reducing thrombus incidence from 70% to 20%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: